Next Article in Journal
Characterization and Functional Analysis of a Novel Fungal Immunomodulatory Protein Gene from Ganoderma leucocontextum in B16-F10 Mouse Melanoma Cells
Previous Article in Journal
Morphological Alterations of Conal Ridges and Differential Expression of AP2α in the Offspring Hearts of Experimental Diabetic Rats
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Photophysical Properties of a Chiral Iridium-Based Photosensitizer as an Efficient Photodynamic Therapy Agent: A Theoretical Investigation

by
Maciej Spiegel
Department of Organic Chemistry and Pharmaceutical Technology, Wroclaw Medical University, Borowska 211 A, 50-556 Wroclaw, Poland
Int. J. Mol. Sci. 2025, 26(11), 5062; https://doi.org/10.3390/ijms26115062
Submission received: 24 April 2025 / Revised: 12 May 2025 / Accepted: 19 May 2025 / Published: 24 May 2025

Abstract

This study employs time-dependent density functional theory to explore the photophysical properties of a chiral iridium(III) complex designed as a photosensitizer for photodynamic therapy. Key properties analyzed include one-photon absorption energies, singlet–triplet energy gaps, spin–orbit coupling constants, and intersystem crossing rate constants. The potential for operation in a Type I PDT mechanism was assessed through ionization potential and electron affinity calculations. The results demonstrate that the complex is a promising PDT candidate, primarily operating in a Type II mechanism, while offering conditional viability for Type I photoreactivity under specific electronic and environmental conditions.

1. Introduction

The discovery of cisplatin’s anticancer properties marked a groundbreaking milestone in oncology, catalyzing extensive research into organometallic compounds aimed at reducing the side effects of conventional chemotherapy. Among emerging alternatives, photodynamic therapy (PDT) stands out as a minimally invasive technique that uses light to activate a photosensitizer, generating cytotoxic species such as singlet oxygen (1Δg O2). Beyond its applications in cancer treatment, PDT has shown promise in antibacterial, antiviral, and environmental contexts [1,2,3].
The photophysical mechanism of PDT involves the excitation of a photosensitizer within the therapeutic window (400–900 nm), followed by efficient intersystem crossing (ISC) from the first excited singlet state (S1) to a triplet state (Tn). If the triplet state energy exceeds 0.98 eV, the energy transfer to ground-state triplet oxygen (3O2) produces cytotoxic 1Δg O2—a hallmark of the Type II mechanism. An ideal photosensitizer should meet several criteria: non-cytotoxicity in the dark, water solubility, redox stability, and strong absorption in the higher-frequency region of the therapeutic window for enhanced tissue penetration. Additionally, it should minimize fluorescence and exhibit significant spin–orbit coupling (SOC) to promote ISC—typically achieved through the incorporation of heavy metals into the molecular framework [4].
In photodynamic therapy, Type II mechanisms involve energy transfer from the excited triplet state of a photosensitizer to ground-state triplet oxygen, generating cytotoxic singlet oxygen (1O2). This pathway is oxygen-dependent and highly effective in well-oxygenated tissues. In contrast, Type I mechanisms proceed through electron or hydrogen atom transfer, forming reactive oxygen species (ROS) such as superoxide (O2−•) or hydroxyl radicals (OH), and are more effective under hypoxic conditions. Each mechanism has distinct advantages and limitations. Type II offers high selectivity, predictable reactivity, and minimal side reactions but is ineffective in hypoxic tumors. In contrast, Type I can function under low-oxygen conditions and generate a broader spectrum of reactive oxygen species, although it may suffer from lower specificity, potential off-target effects, and dependence on cellular redox conditions. The ability of a single photosensitizer to access both mechanisms—depending on its electronic structure and environment—offers flexibility and therapeutic adaptability [5,6,7].
In recent years, complexes of ruthenium(II), iridium(III), and osmium(II) have been synthesized and characterized for their promising photophysical properties in PDT [8,9,10,11]. Notably, Wang et al. reported a pair of enantiopure mononuclear Ir(III) complexes to explore enantiomer-dependent anticancer activity [9]. Despite having identical structural and spectroscopic profiles, the enantiomers demonstrated different efficacies against specific cancer cell lines, indicating that chirality plays a critical role in therapeutic performance.
To elucidate the photophysical properties underlying PDT efficacy in such systems, this study employs density functional theory—a computational approach previously validated for analyzing second-row transition metal complexes in PDT research [12,13,14,15,16].

2. Results and Discussion

2.1. Structural Parameters

The optimized geometry of the iridium-based complex reveals a pseudo-octahedral coordination environment around the metal center. The electron-donating thiophene group is coplanar with the imidazo-phenanthroline moiety, while the other two thiophene rings deviate slightly from coplanarity. This configuration is preserved across the ground state (S0), first excited singlet (S1), and first excited triplet (T1), as shown in Figure 1.
The Ir–N bond lengths (Table 1) indicate that the bonds to the imidazo-phenanthroline nitrogens (D1, D2) are slightly longer than those of the phenylatopyridine ligands (D3, D6), which are, in turn, longer than the Ir-C bonds in the same ligands (D4, D5). These values are in close agreement with experimental X-ray data for similar iridium complexes, which report Ir–N distances of 2.159 Å (phenanthroline) and 2.040 Å (bipyridine) (bipyridine) [17], validating the computational model.

2.2. Excitation Energies and Absorption Spectra

The computed vertical excitation energies (Table 2) and simulated absorption spectrum (Figure 2) indicate that the most intense absorption peak corresponds to the S1 excitation at 470 nm, aligning well with experimental observations. Charge transfer analysis (Figure 3) reveals an intra-ligand charge transfer from the thiophene moieties to the imidazo-phenanthroline core, a trend consistent with previous studies of transition metal complexes.
Three triplet states (T1–T3) lie below S1, each possessing energies exceeding the 0.98 eV threshold required for Type II PDT. The first triplet state (T1) at 658 nm also closely matches the experimental value of 647 nm, as determined by nanosecond time-resolved transient absorption spectroscopy [9]. This T1 transition is predominantly characterized by the highest occupied molecular orbital to the lowest unoccupied molecular orbital transition (H → L, 63.6%), with a secondary contribution from H → L + 1 (26.6%). The T2 state is primarily dominated by a H → L + 1 (52.5%) transition, with smaller contributions from H → L (25.5%) and H − 2 → L (10.4%). In the T3 state, the excitation consists mainly of nearly equal contributions from H − 1 → L and H − 1 → L + 1 transitions. Although T3 is nearly isoenergetic with S1, its optimized geometry exhibits slightly higher energy (by 0.1 eV).

2.3. Spin–Orbit Coupling and Intersystem Crossing

The spin–orbit coupling constants for the S1–T1, S1–T1 and S1–T3 intersystem crossing processes (Table 3), calculated at the optimized triplet geometries, are comparable to values reported for ruthenium-based complexes [18] and are sufficient to facilitate efficient ISC. The S1–T3 pathway, although slightly higher in energy than S1, is particularly favorable due to its large SOC value (317.76 cm⁻1), resulting in a high ISC rate constant (kISC = 3.71 × 109 s⁻1). Interestingly, the S1–T2 intersystem crossing, despite its much lower SOC of 3.95 cm−1, still yields a substantial kISC of 1.77 × 109 s⁻1, which is comparable in magnitude. This suggests that small energy gaps between states can compensate for low coupling strengths, enabling effective triplet population. The complex’s weak fluorescence, indicative of rapid ISC, supports these computational predictions and reinforces its suitability for PDT.

2.4. Type I Mechanism

As stated earlier, PDT can also proceed in Type I mechanisms, generating O2−•. Vertical electron affinities (VEA) and ionization potentials (VIP) were calculated as follows:
VEA:  −2.64 eV (Ps),  −4.18 eV (3Ps*),  −3.62 eV (3O2),
VIP:  5.28 eV (Ps),  3.66 eV (3Ps*).
The feasibility of the following autoionization reactions was evaluated:
3Ps* + Ps → Ps+• + Ps−•,
3Ps* + 3Ps* → Ps+• + Ps−•.
Reaction (2), which involves two triplet-state photosensitizers, is favorable due to its negative energy (−0.52 eV), computed as a sum of VIP (Ps) and VEA (3Ps*). In contrast, Reaction (1) is not favorable, yielding a positive energy (1.10 eV) from the sum of VIP and VEA of 3Ps*. The following subsequent reactions for O2−• production were also considered:
Ps−• + 3O2 → Ps + O2−•,
3Ps* + 3O2 → Ps+• + O2−•.
Reaction (3) is thermodynamically feasible, with an energy change of −0.98 eV (VEA (3O2) + [−VIP (Ps)]). Reaction (4), on the other hand, results in a slightly positive energy change (0.04 eV), suggesting it is less favorable, though potential numerical uncertainties may still allow it to occur. Thus, the production of O2−• is most likely from the Reaction (3) and overall outcomes support a plausible Type I mechanism under certain conditions.
In summary, the complex is expected to operate primarily through a Type II mechanism under normoxic conditions due to its efficient singlet oxygen generation. However, under hypoxic conditions—where O2 availability is limited—or in electron-rich environments [19], such as cells with high metabolic activity or the presence of reducing biomolecules like thiols, phenols, or other electron donors, Type I processes become favored, including the formation of superoxide through electron transfer from the excited triplet state [20].

3. Materials and Methods

Geometry optimizations for both isomeric forms of the complex were performed using the Orca 6.0 software package [21]. Calculations employed the B3LYP functional formulated in the Gaussian way [22,23], along with the x2c-SVPall basis set, within the exact two-component (X2C) relativistic Hamiltonian framework [24] to account for relativistic effects. Solvent interactions (acetonitrile) were modeled using the SMD implicit solvation approach [25], and dispersion interactions were corrected using Grimme’s D4 empirical method [26].
All optimized geometries were confirmed as true minima by vibrational frequency analysis, which showed no imaginary frequencies. Spin–orbit coupling (SOC) elements were calculated at the optimized geometry of the T1 state. These data—including geometries, Hessians, and SOC matrices—were subsequently used in excited-state dynamics simulations to determine intersystem crossing and fluorescence rate constants. Charge transfer behavior was analyzed through hole–electron decomposition using Multiwfn 3.8 [27,28] while molecular visualizations were generated with UCSF Chimera 1.19 [29].

4. Conclusions

This DFT-based quantum chemical investigation of a recently synthesized chiral iridium(III) imidazo-phenanthroline complex provides compelling evidence of its potential as an effective photosensitizer for photodynamic therapy. The key findings of this study are summarized as follows:
  • The optimized geometrical parameters, particularly the Ir-N bond lengths, are in good agreement with experimental X-ray crystallographic data for analogous iridium complexes, validating the computational approach.
  • The calculated vertical excitation energies accurately reproduce the experimental absorption spectrum. Notably, the S1 absorption peak at ~470 nm is attributed to an intra-ligand charge transfer from the thiophene substituents to the imidazo-phenanthroline core, consistent with observed optical behavior.
  • Spin–orbit coupling between singlet and triplet states, particularly in the S1–T2 and S1–T3 pathways, is sufficient to enable rapid intersystem crossing. This supports an efficient Type II PDT mechanism via singlet oxygen generation.
  • Thermodynamic analysis indicates that electron transfer leading to superoxide formation is feasible under certain conditions—specifically when the photosensitizer is in the singlet excited state—suggesting that both Type I and Type II PDT mechanisms are accessible.
  • These results position the chiral iridium complex as a versatile and promising candidate for PDT applications. Future work will focus on experimental validation, phototoxicity assessments, and structural optimization to enhance therapeutic performance and selectivity.

Funding

The APC was funded by Wroclaw Medical University (REZD.Z506.25.002).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Acknowledgments

Created using resources provided by Wroclaw Centre for Networking and Supercomputing (http://wcss.pl).

Conflicts of Interest

The author declares no conflicts of interest.

References

  1. DeRosa, M. Photosensitized Singlet Oxygen and Its Applications. Coord. Chem. Rev. 2002, 233–234, 351–371. [Google Scholar] [CrossRef]
  2. Agostinis, P.; Berg, K.; Cengel, K.A.; Foster, T.H.; Girotti, A.W.; Gollnick, S.O.; Hahn, S.M.; Hamblin, M.R.; Juzeniene, A.; Kessel, D.; et al. Photodynamic Therapy of Cancer: An Update. CA A Cancer J. Clin. 2011, 61, 250–281. [Google Scholar] [CrossRef] [PubMed]
  3. Dabrowski, J.M.; Arnaut, L.G. Photodynamic Therapy (PDT) of Cancer: From Local to Systemic Treatment. Photochem. Photobiol. Sci. 2015, 14, 1765–1780. [Google Scholar] [CrossRef] [PubMed]
  4. Yano, S.; Hirohara, S.; Obata, M.; Hagiya, Y.; Ogura, S.; Ikeda, A.; Kataoka, H.; Tanaka, M.; Joh, T. Current States and Future Views in Photodynamic Therapy. J. Photochem. Photobiol. C. Photochem. Rev. 2011, 12, 46–67. [Google Scholar] [CrossRef]
  5. Spiegel, M. On the Photosensitizing Properties of Aloe-Emodin in Photodynamic Therapy: Insights from the Molecular Modeling. J. Phys. Chem. B 2025. [Google Scholar] [CrossRef]
  6. Sobhani, N.; Samadani, A.A. Implications of Photodynamic Cancer Therapy: An Overview of PDT Mechanisms Basically and Practically. J. Egypt Natl. Canc. Inst. 2021, 33, 34. [Google Scholar] [CrossRef]
  7. Correia, J.H.; Rodrigues, J.A.; Pimenta, S.; Dong, T.; Yang, Z. Photodynamic Therapy Review: Principles, Photosensitizers, Applications, and Future Directions. Pharmaceutics 2021, 13, 1332. [Google Scholar] [CrossRef]
  8. Spiegel, M.; Adamo, C. Tuning the Photophysical Properties of Ru(II) Photosensitizers for PDT by Protonation and Metallation: A DFT Study. J. Phys. Chem. A 2023, 127, 3625–3635. [Google Scholar] [CrossRef]
  9. Wang, W.; Wang, L.; Zhang, Y.; Shi, Y.; Zhang, R.; Chen, L.; Shi, Z.; Yuan, S.; Li, X.; He, C.; et al. Chiral Iridium-Based TLD-1433 Analogues: Exploration of Enantiomer-Dependent Behavior in Photodynamic Cancer Therapy. Inorg. Chem. 2024, 63, 7792–7798. [Google Scholar] [CrossRef]
  10. Roque, J.A.; Barrett, P.C.; Cole, H.D.; Lifshits, L.M.; Bradner, E.; Shi, G.; Von Dohlen, D.; Kim, S.; Russo, N.; Deep, G.; et al. Os(II) Oligothienyl Complexes as a Hypoxia-Active Photosensitizer Class for Photodynamic Therapy. Inorg. Chem. 2020, 59, 16341–16360. [Google Scholar] [CrossRef]
  11. Shi, G.; Monro, S.; Hennigar, R.; Colpitts, J.; Fong, J.; Kasimova, K.; Yin, H.; DeCoste, R.; Spencer, C.; Chamberlain, L.; et al. Ru(II) Dyads Derived from α-Oligothiophenes: A New Class of Potent and Versatile Photosensitizers for PDT. Coord. Chem. Rev. 2015, 282–283, 127–138. [Google Scholar] [CrossRef]
  12. Roque, J.A.; Barrett, P.C.; Cole, H.D.; Lifshits, L.M.; Shi, G.; Monro, S.; Von Dohlen, D.; Kim, S.; Russo, N.; Deep, G.; et al. Breaking the Barrier: An Osmium Photosensitizer with Unprecedented Hypoxic Phototoxicity for Real World Photodynamic Therapy. Chem. Sci. 2020, 11, 9784–9806. [Google Scholar] [CrossRef]
  13. Spiegel, M.; Russo, N. Understanding the Photophysical Properties of Pd and Pt Transition-Metal Isocorroles: A Theoretical Investigation. Chem. A Eur. J. 2025, 31, e202403725. [Google Scholar] [CrossRef]
  14. Alberto, M.E.; De Simone, B.C.; Liuzzi, S.; Marino, T.; Russo, N.; Toscano, M. Iodine Substituted Phosphorus Corrole Complexes as Possible Photosensitizers in Photodynamic Therapy: Insights from Theory. J. Comput. Chem. 2020, 41, 1395–1401. [Google Scholar] [CrossRef]
  15. Alberto, M.E.; Russo, N.; Adamo, C. Synergistic Effects of Metals in a Promising RuII −PtII Assembly for a Combined Anticancer Approach: Theoretical Exploration of the Photophysical Properties. Chem. A Eur. J. 2016, 22, 9162–9168. [Google Scholar] [CrossRef] [PubMed]
  16. Roque Iii, J.A.; Cole, H.D.; Barrett, P.C.; Lifshits, L.M.; Hodges, R.O.; Kim, S.; Deep, G.; Francés-Monerris, A.; Alberto, M.E.; Cameron, C.G.; et al. Intraligand Excited States Turn a Ruthenium Oligothiophene Complex into a Light-Triggered Ubertoxin with Anticancer Effects in Extreme Hypoxia. J. Am. Chem. Soc. 2022, 144, 8317–8336. [Google Scholar] [CrossRef]
  17. Graf, M.; Siegmund, D.; Gothe, Y.; Metzler-Nolte, N.; Sünkel, K. Metal and Substituent Influence on the Cytostatic Activity of Cationic Bis-cyclometallated Iridium and Rhodium Complexes with Substituted 1,10-Phenanthrolines as Ancillary Ligands. Z. Anorg. Allge. Chem. 2020, 646, 665–669. [Google Scholar] [CrossRef]
  18. Alberto, M.E.; Pirillo, J.; Russo, N.; Adamo, C. Theoretical Exploration of Type I/Type II Dual Photoreactivity of Promising Ru(II) Dyads for PDT Approach. Inorg. Chem. 2016, 55, 11185–11192. [Google Scholar] [CrossRef] [PubMed]
  19. Ding, H.; Yu, H.; Dong, Y.; Tian, R.; Huang, G.; Boothman, D.A.; Sumer, B.D.; Gao, J. Photoactivation Switch from Type II to Type I Reactions by Electron-Rich Micelles for Improved Photodynamic Therapy of Cancer Cells under Hypoxia. J. Control. Release 2011, 156, 276–280. [Google Scholar] [CrossRef]
  20. Wu, Y.; Li, S.; Chen, Y.; He, W.; Guo, Z. Recent Advances in Noble Metal Complex Based Photodynamic Therapy. Chem. Sci. 2022, 13, 5085–5106. [Google Scholar] [CrossRef]
  21. Neese, F. Software Update: The ORCA Program System—Version 5.0. WIREs Comput. Mol. Sci. 2022, 12, e1606. [Google Scholar] [CrossRef]
  22. Lee, C.; Yang, W.; Parr, R.G. Development of the Colle-Salvetti Correlation-Energy Formula into a Functional of the Electron Density. Phys. Rev. B 1988, 37, 785–789. [Google Scholar] [CrossRef] [PubMed]
  23. Becke, A.D. Density-Functional Thermochemistry. III. The Role of Exact Exchange. J. Chem. Phys. 1993, 98, 5648–5652. [Google Scholar] [CrossRef]
  24. Pollak, P.; Weigend, F. Segmented Contracted Error-Consistent Basis Sets of Double- and Triple-ζ Valence Quality for One- and Two-Component Relativistic All-Electron Calculations. J. Chem. Theory Comput. 2017, 13, 3696–3705. [Google Scholar] [CrossRef]
  25. Marenich, A.V.; Cramer, C.J.; Truhlar, D.G. Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. J. Phys. Chem. B 2009, 113, 6378–6396. [Google Scholar] [CrossRef]
  26. Bursch, M.; Neugebauer, H.; Ehlert, S.; Grimme, S. Dispersion Corrected r2SCAN Based Global Hybrid Functionals: r2SCANh, r2SCAN0, and r2SCAN50. J. Chem. Phys. 2022, 156, 134105. [Google Scholar] [CrossRef]
  27. Lu, T. A Comprehensive Electron Wavefunction Analysis Toolbox for Chemists, Multiwfn. J. Chem. Phys. 2024, 161, 082503. [Google Scholar] [CrossRef]
  28. Lu, T.; Chen, F. Multiwfn: A Multifunctional Wavefunction Analyzer. J. Comput. Chem. 2012, 33, 580–592. [Google Scholar] [CrossRef]
  29. Pettersen, E.F.; Goddard, T.D.; Huang, C.C.; Couch, G.S.; Greenblatt, D.M.; Meng, E.C.; Ferrin, T.E. UCSF Chimera—A Visualization System for Exploratory Research and Analysis. J. Comput. Chem. 2004, 25, 1605–1612. [Google Scholar] [CrossRef]
Figure 1. Superimposed structures of the ground state (S0, light brown), first excited singlet state (S1, cyan), and first excited triplet state (T1, pink) of the studied complex.
Figure 1. Superimposed structures of the ground state (S0, light brown), first excited singlet state (S1, cyan), and first excited triplet state (T1, pink) of the studied complex.
Ijms 26 05062 g001
Figure 2. Simulated absorption spectrum of the studied complex.
Figure 2. Simulated absorption spectrum of the studied complex.
Ijms 26 05062 g002
Figure 3. Hole (blue) and electron (green) charge transfer depiction for S1 excitation.
Figure 3. Hole (blue) and electron (green) charge transfer depiction for S1 excitation.
Ijms 26 05062 g003
Table 1. Ir–N bond lengths (Å) for ground state (S0), first excited singlet (S1), and first excited triplet (T1).
Table 1. Ir–N bond lengths (Å) for ground state (S0), first excited singlet (S1), and first excited triplet (T1).
Ijms 26 05062 i001
StateD1D2D3D4D5D6
S02.1872.1872.0702.0162.0162.070
S12.1562.1522.0542.0112.0112.054
T12.1572.1562.0552.0102.0102.055
Table 2. Vertical excitation energies (ΔE, eV), wavelengths (λ, nm), oscillator strengths (f), and main transitions (%) in dichloromethane.
Table 2. Vertical excitation energies (ΔE, eV), wavelengths (λ, nm), oscillator strengths (f), and main transitions (%) in dichloromethane.
StateEλfTransition (%)
T11.88658.00.997H → L (63.6%)
H → L + 1 (26.6%)
T22.50495.60.997H → L (25.5%)
H → L + 1 (52.5%)
H − 2 → L (10.4%)
T32.61474.30.997H − 1 → L (44.8%)
H − 1 → L + 1 (41.6%)
S12.64470.00.997H → L (86.6%)
H → L + 1 (9.1%)
Table 3. Computed energy gaps (ΔE(S₁-Tⱼ), in eV), spin–orbit couplings (SOCs, in cm−1), and intersystem crossing rate constants (kISC, in s−1).
Table 3. Computed energy gaps (ΔE(S₁-Tⱼ), in eV), spin–orbit couplings (SOCs, in cm−1), and intersystem crossing rate constants (kISC, in s−1).
T ΔE(S₁-Tⱼ)SOCkISC
T10.740.285.73 × 102
T20.033.951.77 × 109
T3−0.07217.763.71 × 109
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Spiegel, M. Photophysical Properties of a Chiral Iridium-Based Photosensitizer as an Efficient Photodynamic Therapy Agent: A Theoretical Investigation. Int. J. Mol. Sci. 2025, 26, 5062. https://doi.org/10.3390/ijms26115062

AMA Style

Spiegel M. Photophysical Properties of a Chiral Iridium-Based Photosensitizer as an Efficient Photodynamic Therapy Agent: A Theoretical Investigation. International Journal of Molecular Sciences. 2025; 26(11):5062. https://doi.org/10.3390/ijms26115062

Chicago/Turabian Style

Spiegel, Maciej. 2025. "Photophysical Properties of a Chiral Iridium-Based Photosensitizer as an Efficient Photodynamic Therapy Agent: A Theoretical Investigation" International Journal of Molecular Sciences 26, no. 11: 5062. https://doi.org/10.3390/ijms26115062

APA Style

Spiegel, M. (2025). Photophysical Properties of a Chiral Iridium-Based Photosensitizer as an Efficient Photodynamic Therapy Agent: A Theoretical Investigation. International Journal of Molecular Sciences, 26(11), 5062. https://doi.org/10.3390/ijms26115062

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop